Donepezil in the treatment of progressive supranuclear palsy

Acta Neurologica Scandinavica

Volumn 103, Issue 2, 2001, Pages 123-125

  Fabbrini, G ^a,b   Barbanti, P ^a   Bonifati, V ^a   Colosimo, C ^a   Gasparini, M ^a   Vanacore, N ^a   Meco, G ^a  

^a SAPIENZA UNIVERSITY OF ROME   (Italy)

^b SAPIENZA UNIVERSITY OF ROME   (Italy)

Author keywords

Donepezil; Progressive supranuclear palsy

Indexed keywords

DONEPEZIL;

AGED; ARTICLE; CLINICAL ARTICLE; COGNITION; DAILY LIFE ACTIVITY; DRUG EFFICACY; FEMALE; HUMAN; MALE; MONOAMINERGIC SYSTEM; MOTOR PERFORMANCE; PARKINSON DISEASE; PROGRESSIVE SUPRANUCLEAR PALSY;

AGED; CHOLINESTERASE INHIBITORS; COGNITION DISORDERS; FEMALE; HUMANS; INDANS; MALE; MIDDLE AGED; NEUROPSYCHOLOGICAL TESTS; PIPERIDINES; SEVERITY OF ILLNESS INDEX; SUPRANUCLEAR PALSY, PROGRESSIVE;

EID: 0035154265     PISSN: 00016314     EISSN: None     Source Type: Journal    
DOI: 10.1034/j.1600-0404.2001.103002123.x     Document Type: Article

References (13)

1. Progressive supranuclear palsy. A heterogenous degeneration involving the brain stem, basal ganglia and cerebellum, with vertical gaze and pseudobulbar palsy, nuclear dystonia and dementia
2. Dopaminergic and cholinergic lesions in progressive supranuclear palsy
3. Striosomes and extrastriosomal matrix contain different amounts of immunoreactive choline acetyltransferase in the human striatum
4. Mesencephalic cholinergic nuclei in progressive supranuclear palsy
5. Neuronal loss in the basal nucleus of Meynert in progressive supranuclear palsy
6. Pharmacological evaluation of the cholinergic system in progressive supranuclear palsy
7. Physostigmine treatment of progressive supranuclear palsy
8. Cognitive deficits in progressive supranuclear palsy, Parkinson's disease, and multiple system atrophy in tests sensitive to frontal lobe dysfunction
9. Neuropsychological features of Progressive Supranuclear Palsy
10. A 24-week, double blind, placebo-controlled trial of donepezil in patients with Alzheimer's disease
11. Prevalence and natural history of progressive supranuclear palsy
12. Pharmacological therapy in progressive supranuclear palsy
13. Does the enhancement of cholinergic neurotransmission influence brain glucose kinetics and clinical symptomatology in progressive supranuclear palsy?